StockNews.com Downgrades Omnicell (NASDAQ:OMCL) to Hold

Omnicell (NASDAQ:OMCL) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Friday.

Other equities analysts also recently issued reports about the stock. Bank of America reiterated a “neutral” rating and issued a $57.00 price objective (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Barclays raised their target price on shares of Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. lifted their target price on Omnicell from $26.00 to $37.00 and gave the company a “neutral” rating in a research report on Friday, August 23rd. Craig Hallum upped their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Benchmark restated a “buy” rating and set a $48.00 price target on shares of Omnicell in a report on Wednesday, October 9th. Five equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $50.83.

Omnicell Trading Down 2.0 %

Shares of OMCL stock traded down $0.93 during trading hours on Friday, hitting $45.67. 393,731 shares of the company were exchanged, compared to its average volume of 526,537. The business has a 50 day moving average of $44.19 and a two-hundred day moving average of $36.70. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74. The company has a market capitalization of $2.12 billion, a PE ratio of -117.10, a PEG ratio of 46.03 and a beta of 0.81.

Hedge Funds Weigh In On Omnicell

Large investors have recently bought and sold shares of the stock. Nisa Investment Advisors LLC lifted its position in shares of Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after purchasing an additional 1,000 shares during the period. GAMMA Investing LLC lifted its stake in Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares during the period. EntryPoint Capital LLC lifted its holdings in shares of Omnicell by 121.2% during the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after buying an additional 1,345 shares during the period. CWM LLC grew its stake in shares of Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after purchasing an additional 1,236 shares during the period. Finally, 1620 Investment Advisors Inc. raised its holdings in Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock worth $96,000 after purchasing an additional 1,542 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.